Get started
PFIZERPFIZERPFIZER

PFIZER

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Bonds

1PFE trade ideas

Pfizer Drops After Pulling Obesity-Drug Study Following PatientPfizer will retool its obesity drug efforts, but the delay is a blow to the group's ambitions to challenge Novo Nordisk and Lilly in the fast-developing space. Pfizer (NYSE: PFE) - shares slumped Friday after the drugmaker said it would not advance a study of its two-dose obesity treatment, following a high level of side effects in patients involved in the Phase II trial. Pfizer said it would instead focus on a single-dose option. Trials of its danuglipron treated showed good results in weight loss but induced vomiting and nausea in patients, which led to what it called "high discontinuation rates" compared with those taking a placebo. Pfizer's Mikael Dolsten, president of worldwide research and development, in late October called the danuglipron study "our main opportunity here for getting data to review for obesity, in fact, to diabetes" in a call with investors. For Pfizer, a Setback in Weight-loss Market The decision marks a significant setback in Pfizer's ambitions to enter the weight-loss drug market, which is currently dominated by Novo Nordisk's Wegovy. Pfizer rival Eli Lilly (LLY) - Get Free Report last month also won approval for its own weight-loss treatment, Zepbound, from the Food and Drug Administration. At last check Pfizer stock was trading off 4.7% just above $28.91 That's a bit more than half its 52-week high near $55, set in mid-December 2022. Pfizer in October slashed its full-year sales and profit forecasts amid a slump in demand for covid treatments, It told investors it would write off around $4.6 billion in inventories of Paxlovid, its oral covid treatment, while taking a further $5.5 billion noncash charge against its third-quarter earnings. Price Momentum PFE is trading near the bottom of its 52-week range and below its 200-day simple moving average. What does this mean? Investors have been pushing the share price lower, and the stock still appears to have downward momentum. This is a negative sign for the stock's future value.
NYSE:PFEShort
by DEXWireNews
Pfizer: Big Pharma struggles in the post-COVID timesPfizer Inc. shares have reached their lowest levels since March 2020, during the height of the coronavirus pandemic. Since the beginning of 2023, the issuer's securities have declined due to reduced revenue from drug and COVID-19 vaccine sales. However, Pfizer's potential is not exhausted, as the company intends to introduce a new drug called Danuglipron to combat excess weight in the coming weeks. So today, let's look at the Pfizer Inc (NYSE: PFE) stock chart. On the D1 timeframe, support formed at 28.93, and resistance moved to 31.39. Quotes consolidated above the crucial level of 30.14. On the H1 timeframe, if there is a rebound from the 30.14 level, the target for a price increase can be placed at 33.98. In the medium term, the price could potentially reach 40.15. — Ideas and other content presented on this page should not be considered as guidance for trading or an investment advice. RoboMarkets bears no responsibility for trading results based on trading opinions described in these analytical reviews. The material presented and the information contained herein is for information purposes only and in no way should be considered as the provision of investment advice for the purposes of Investment Firms Law L. 87(I)/2017 of the Republic of Cyprus or any other form of personal advice or recommendation, which relates to certain types of transactions with certain types of financial instruments. Risk Warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 67.85% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
NYSE:PFE
by RoboMarkets
Pfizer long-term movement after a deep correction - risky paperH i, I looked at Pfizer's chart and it looks like this deep correction won't stop until the $30 zone. The fact that side effects have developed worldwide due to the Covid vaccine and many people have filed lawsuits against pharmaceutical companies probably also plays a role in this deep decline. There is a lot of money in the pharmaceutical industry, so I think that the companies will have plenty of money to cover possible legal costs. And since in several countries they have signed papers that they request the vaccination on their own responsibility, the exclusion of liability will be justified in many cases. The $30 zone seems like a perfect turning point because I see it as a strong level. If the $30 zone holds, we will most likely look at the $40 zone, which also coincides with an important Fibonacci level. Do not forget. This does not constitute investment advice. Do your own research before entering a position. Regards In extreme cases, the $27 level is also possible.
NYSE:PFE
by XOX_XOX
1
Let's Buy Some Phizer!Analysis of Pfizer Inc. (PFE) on NYSE (Monthly Timeframe) The provided chart exhibits the long-term price movement of Pfizer Inc. on the New York Stock Exchange, with data captured on a monthly timeframe, extending over a period from roughly 2006 to the current date. Observations: The PFE stock observed a substantial rally that commenced around 2018, propelling the price to reach an apex slightly above $61.71. Post its peak, a pronounced correction is evident, causing the stock to retreat to its current price region near $31.16. The Fibonacci retracement levels on the chart highlight pivotal zones of potential resistance and support. As of now, the stock is oscillating near the 0.5 retracement level ($34.09). Over the longer term, the stock has been largely range-bound, especially between 2006 to 2018, indicating regions of historical resistance and support. The Relative Strength Index (RSI) and the Stochastic Oscillator reflect a bearish momentum with the potential for some upside, considering they are in or approaching the oversold region. Short to Mid-Term Targets: Immediate support appears to be at the 0.618 Fibonacci level ($29.75). Should the price maintain above this level, the immediate resistance to watch would be the 0.5 level ($34.09). Beyond this, the 0.382 level at approximately $42.37 presents the next significant resistance. Long-Term Perspective: Should the stock regain bullish momentum, overcoming the historical peak around $61.71 would be crucial for setting the stage for potential new highs. Conversely, if the downtrend continues and breaches the 0.618 level ($29.75), the stock may seek support around its previous low regions, notably close to $20. Conclusion: Investors are encouraged to pay heed to the evolving price dynamics and corroborate the technical indications with other relevant market news or potential catalysts. As always, considering protective measures like setting a stop-loss can aid in risk management.
NYSE:PFELong
by kargaa
PFE - BULLISH SCENARIOPfizer (NYSE:PFE) gained EU antitrust approval for its $43 billion acquisition of Seagen, a cancer drug maker. This acquisition, announced in March, is Pfizer's largest recent purchase, fueled by the financial success of its COVID-19 vaccines and treatments. The European Commission found no significant competition or pricing concerns in the 27-country European Union, stating that the merger doesn't raise competition issues. Seagen, based in Washington, specializes in antibody-drug conjugates designed to selectively destroy cancer cells, sparing healthy ones. Risk Disclosure: Trading Foreign Exchange (Forex) and Contracts of Difference (CFD's) carries a high level of risk. By registering and signing up, any client affirms their understanding of their own personal accountability for all transactions performed within their account and recognizes the risks associated with trading on such markets and on such sites. Furthermore, one understands that the company carries zero influence over transactions, markets, and trading signals, therefore, cannot be held liable nor guarantee any profits or losses.
NYSE:PFELong
by legacyFXofficial
1
Pfizer's (PFE) Ulcerative Colitis Pill Etrasimod Gets FDA NodPfizer PFE announced that the FDA has granted approval to its oral, once-daily pill called etrasimod to treat moderately-to-severely active ulcerative colitis (UC). The oral, once-daily, selective sphingosine-1-phosphate (S1P) receptor modulator will be marketed by the brand name of Velsipity (2 mg dose). The approval for etrasimod was based on data from two pivotal phase III studies, ELEVATE UC 52 and ELEVATE 12. These studies evaluated the safety and efficacy of a daily 2mg dose of oral etrasimod in UC patients who had failed treatment with a JAK inhibitor. Both studies achieved their primary endpoint of clinical remission over placebo and all key secondary endpoints. An application seeking the approval of etrasimod is also under review in the EU, with a decision from the European Medicines Agency anticipated in first-half 2024. Velsipity (etrasimod) was added to Pfizer’s inflammation and immunology portfolio with the March 2022 acquisition of Arena Pharmaceuticals. The oral, once-daily pill for UC, a chronic condition, is an advanced therapy, which, if approved, will offer patients an opportunity to achieve steroid-free remission. Pfizer’s stock has declined 37.4% so far this year against an increase of 8.5% for the industry.
NYSE:PFELong
by DEXWireNews
Pfizer's Stock: Is it Worth the Investment ?Pfizer's Stock: Is it Worth the Investment Amidst Challenges and Opportunities? Pfizer, a pharmaceutical powerhouse, has made headlines in recent years, primarily for its groundbreaking coronavirus vaccine. Despite achieving over $100 billion in annual revenue last year, the company's stock has witnessed a significant decline of approximately 35% in the current year. This prompts the question: Why has Pfizer's share price dipped despite robust financial performance, and is it still a worthwhile investment? In this article, we'll delve into the factors affecting Pfizer's stock and assess whether it presents an attractive investment opportunity. Challenges on the Horizon The decline in Pfizer's stock can be attributed to investor concerns regarding the sustainability of vaccine sales in a post-pandemic world. As vaccine demand wanes, the company faces declining revenues from products like Comirnaty and Paxlovid, with projections of double-digit revenue declines compared to the previous year. Moreover, Pfizer is grappling with the imminent patent expirations of key drugs like Eliquis and Ibrance, which could result in revenue losses totaling $17 billion from 2025 through 2030. Assessing the Risks Pfizer's transition from government contracts to commercial sales introduces some risk, as commercial purchasers typically do not commit to extensive supply agreements years in advance. Additionally, the looming patent cliff poses a revenue challenge that Pfizer must address. Positive Developments Despite these challenges, Pfizer has several positive developments to consider. Comirnaty and Paxlovid may still provide steady recurring revenue, albeit at lower levels. Pfizer envisions the coronavirus market evolving into something akin to the flu shot market, potentially generating substantial billion-dollar revenue, given its market leadership. Earnings from coronavirus-related products have empowered Pfizer to pursue acquisitions and initiatives to fuel long-term growth. Last year, Pfizer acquired four companies expected to contribute over $10 billion to revenue by 2030. Furthermore, a planned acquisition of oncology specialist Seagen could add an additional $10 billion in revenue. Addressing the patent cliff, Pfizer is actively working to mitigate revenue losses. It anticipates generating $20 billion in revenue by 2030 from ongoing product launches. The company is midway through its most substantial wave of product releases, aiming for 19 launches in an 18-month period, with contributions expected in the latter half of this year. Pfizer projects that business deals, ongoing product launches, and potential pipeline launches could result in non-coronavirus revenue of up to $84 billion in 2030. Is Pfizer a Worthy Investment? Considering these factors, Pfizer appears well-prepared to offset potential revenue losses and foster growth in the years ahead. The revenue outlook for 2030 is promising, even without factoring in coronavirus product sales. Additionally, Pfizer's shares are currently trading at an attractive valuation of around 10 times forward earnings estimates. In conclusion, Pfizer seems to be a prudent investment choice at this juncture. While immediate stock price gains may not be expected, investors entering at the current price point may enjoy dividends in the near term, as Pfizer is committed to rewarding shareholders. Furthermore, the potential for improved share price performance in the future makes Pfizer a compelling investment opportunity amidst its transitional phase. Previous ( Winning ) Idea:
NYSE:PFEShort
by FOREXN1
6
PFIZER Buy signal but only on the short-term.Pfizer (PFE) has been trading within a Channel Down pattern since the start of the year and on Friday it registered the strongest green 1D candle since the recent Lower Low leg started in August. This is technically the start of the new rebound leg towards a new Lower High. Those have been priced within the 1D MA50 (blue trend-line) and 1D MA100 (green trend-line), never breaking above the latter. We are therefore targeting the 1D MA50 again at 34.50, an average estimate based on the previous three Lower High legs. Note that this is only a short-term trade as the long-term trend remains heavily bearish within the Channel Down. Only a 1D candle closing above the 1D MA100 can justify a longer term buy targeting the 1D MA200 (orange trend-line). ------------------------------------------------------------------------------- ** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! ** ------------------------------------------------------------------------------- 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇
NYSE:PFELong
by TradingShot
7
Pfizer (PFE) -> It Is Now Or NeverMy name is Philip, I am a German swing-trader with 4+ years of trading experience and I only trade stocks , crypto , options and indices 🖥️ I only focus on the higher timeframes because this allows me to massively capitalize on the major market swings and cycles without getting caught up in the short term noise. This is how you build real long term wealth! In today's anaylsis I want to take a look at the bigger picture on Pfizer. At the moment Pfizer stock is once again retesting major sructure at the psychological $33 level which already acted as pretty strong support in the past. Considering that the next support level below current price is at $27, Pfizer is now trading at a pretty decisive potential turning point and has not yet broken structure towards the downside. - - - - - - - - - - - - - - - - - - - - I know that this is a quite simple trading approach but over the past 4 years I've realized that simplicity and consistency are much more important than any trading strategy. Keep the long term vision🫡
NYSE:PFELong
by basictradingtv
20